Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDarmwal, Nidhi-
dc.contributor.authorSingh, B K-
dc.contributor.authorChoudhary, Bhanwar S-
dc.contributor.authorSankar, Brajesh-
dc.contributor.authorShanti, Nithya-
dc.identifier.issn0975-0983(Online); 0376-4699(Print)-
dc.description.abstractOrganophosphate (OP) causes phosphorylation of acetylcholinesterase enzyme which leads to accumulation of acetylcholine. This phosphorylation generally occurs due to exposure of nerve agents and intake of pesticides, etc. Various standard drugs specifically oxime derivatives (HI-6, Obidoxime, 2-PAM, etc.) are used as AChE enzyme reactivation agents. These standard drugs show least penetration to CNS. Taking them into consideration with the help of structure and ligand based screened compounds, various small molecules analogues targeting CNS have been designed. These analogues pass all the pharmacokinetic parameters structurally and have also shown better results than that of standards. Among various charged and uncharged analogues, 4g, 4h and 4j have attained docking scores –13.11, –12.84 and –12.75Kcal/mol respectively which is better than that of the standard (HI-6) –12.13kcal/mol.en_US
dc.publisherNIScPR-CSIR, Indiaen_US
dc.sourceIJC-B Vol.60B(06) [June 2021]en_US
dc.subjectLigand based drug designen_US
dc.subjectstructure based drug designen_US
dc.subjectLOPAC databaseen_US
dc.subjectvirtual screeningen_US
dc.subjectanalogue designingen_US
dc.subjectpharmacokinetic parametersen_US
dc.titleAnalogues designing for dephosphorylation of acetylcholinesterase enzymeen_US
Appears in Collections:IJC-B Vol.60B(06) [June 2021]

Files in This Item:
File Description SizeFormat 
IJCB 60B(6) 856-865.pdf1.87 MBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.